Join Us
Sign up for our feature-packed newsletter today to ensure you get the latest expert help and advice to level up your lab work.
While CRISPR offers vast applications in disease research and drug target identification, it’s not always the optimal choice for every scenario. Explore the main advantages and challenges of using CRISPR-Cas9 to determine if it’s the right fit for your project.
Learn how the CRISPR prokaryote immune response systems were first discovered and the development of the CRISPR-Cas9 gene-editing tool.
Want to do some epigenome editing? Discover the usefulness of catalytically inactive (dead) Cas9.
CRISPRa allows you to activate or overexpress genes in a more endogenous manner. Find out the steps to getting started.
Level-up your troubleshooting ability by determining the success of failure of each stage of your CRISPR experiment.
Next-generation sequencing (NGS) has ushered in a new era of understanding of both the inner workings and the function of the genome. NGS allows researchers to look at traits—including diseases—that are linked to differences or mutations in an individual’s genes. Since only about 1% of the human genome constitutes genes that code for proteins, several…
Target capture through PCR has been a mainstay in genomics for years, but scientists working on especially repetitive, poorly characterized, or rapidly evolving regions continue to struggle to fish out those stretches of DNA for further study. However, whole genome sequencing, the only other alternative for these regions, can force researchers to pay for much…
Imagine directly creating a mutation at (almost) any site in your target genome instead of screening thousands or millions of random mutants! The CRISPR/Cas9 system does just that. In its traditional form, this forward genetics approach takes 7 steps from start to mutated genome. However, there is a way to obtain your designer genome in…
Get tips and tricks for performing CRISPR-Cas9 editing in Drosophila.
The eBook with top tips from our Researcher community.